Does PEMBROLIZUMAB Cause Vascular access site complication? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Vascular access site complication have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.0% of all adverse event reports for PEMBROLIZUMAB.
14
Reports of Vascular access site complication with PEMBROLIZUMAB
0.0%
of all PEMBROLIZUMAB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Vascular access site complication From PEMBROLIZUMAB?
Of the 14 reports, 2 (14.3%) required hospitalization.
Is Vascular access site complication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does PEMBROLIZUMAB Cause?
Malignant neoplasm progression (10,111)
Death (4,744)
Diarrhoea (4,251)
Fatigue (3,833)
Off label use (3,416)
Product use in unapproved indication (3,191)
Pyrexia (3,155)
Rash (2,900)
Nausea (2,670)
Decreased appetite (2,486)
What Other Drugs Cause Vascular access site complication?
CONESTAT ALFA (90)
HUMAN C1-ESTERASE INHIBITOR (74)
CARBOPLATIN (8)
PEMETREXED (7)
ASPIRIN (5)
CLOPIDOGREL BISULFATE (5)
Which PEMBROLIZUMAB Alternatives Have Lower Vascular access site complication Risk?
PEMBROLIZUMAB vs PEMETREXED
PEMBROLIZUMAB vs PEMIGATINIB
PEMBROLIZUMAB vs PENICILLAMINE
PEMBROLIZUMAB vs PENICILLIN
PEMBROLIZUMAB vs PENICILLIN G